Hong Kong-listed Edding Genor Group Holdings Limited (Edding Genor, 06998) reported its first set of post-merger annual results for the year ended 31 December 2025.
Revenue and Profitability • Group revenue slipped 2.30% year-on-year to RMB2.49 billion, reflecting softer sales of legacy originator products. • Net profit increased 2.93% to RMB399.26 million, driven by cost optimisation and lower finance expenses. • Adjusted net profit (non-HKFRS) rose to RMB470.65 million, while adjusted EBITDA reached RMB950.37 million. • Overall gross margin improved to 68.2% (2024: 67.4%).
Cash Flow and Balance Sheet • Cash and cash equivalents jumped to RMB1.05 billion (31 Dec 2024: RMB111.70 million), supported by the completion of the merger between Edding Group and Genor Biopharma on 30 December 2025. • Net current liabilities narrowed significantly to RMB10.39 million. • Interest-bearing bank and other borrowings fell 35.4% to RMB1.44 billion, lowering the gearing ratio to 41.7% (2024: 55.7%). • Goodwill and other intangible assets expanded to RMB3.64 billion, reflecting the fair-value consolidation of Genor Biopharma’s assets.
Product Performance • Originator-branded drugs contributed RMB2.17 billion in gross sales (-9.5% YoY), led by Vancocin (RMB1.24 billion) and Ceclor (RMB0.81 billion). • Innovative products generated RMB327.36 million (+4.0% YoY). Vascepa sales climbed 144% to RMB189.05 million, offsetting a 46.1% decline in Mulpleta. Newly launched breast-cancer therapy Rujianing booked RMB10.49 million post-approval. • Six of seven commercialised products are now listed on China’s National Reimbursement Drug List, including 2025 additions Rujianing and Jing Zhu Da.
Cost Structure • Selling and distribution expenses fell 9.2% to RMB598.61 million following tighter conference and personnel spending. • R&D expenses rose 33.4% to RMB162.56 million, reflecting advancement of key clinical programmes GB268 (trispecific antibody) and EDP167 (ANGPTL3 siRNA). • Net finance costs were cut by 45.6% to RMB138.53 million after loan restructurings.
Strategic Progress • The December 2025 reverse takeover created China’s first Chapter 18A biotech RTO, combining Edding’s commercial platform with Genor’s oncology and autoimmune pipeline. • Post-merger, the Group controls seven marketed drugs and three clinical assets across oncology, autoimmune, cardiovascular, respiratory and anti-infective areas. • Key pipeline milestones include Phase II initiation for EDP167 in HoFH patients (Feb 2026) and planned Phase II start for GB268 in 4Q 2026.
Governance Updates • Dr. Han Shuhua was appointed executive director effective 27 March 2026, succeeding Ms. Zhai Jing. • Mr. Ni Xin, already chairman, has assumed the role of chief executive officer following Dr. Guo Feng’s resignation.
Outlook Management positions 2026 as a “year of integration”, targeting accelerated commercial ramp-up of innovative therapies, disciplined R&D investment in high-potential assets, and enhanced operational efficiency to sustain growth.
Comments